Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 362

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 362
---
 Company has identified the following off-balance sheet commitments as of December 31, 2024:

• non-cancellable purchase commitments as of December 31, 2024 for a total of € 7,687 2,750 4,938

• On July 3, 2017, Innate Pharma borrowed from the bank Société Générale in order to finance the construction of its future headquarters. As security for the loan, Innate pledged collateral in the form of financial instruments held at Société Générale amounting to € 15.2 4,200 5,000 6,000 8,894 4,200

• The Company has entered into indemnification agreements with its directors & officers (the « Beneficiaries »), under which (1) Company will provide to the Beneficiaries the benefit of one or more director and officer (“ D& O”) insurance policies and (2) if not indemnifiable under the D& O insurance policy, the Beneficiary shall be compensated for any indemnifiable claim by the Company to the fullest extent permitted by law.

Licensing and collaboration agreements

Commitments related the Company’s licensing and collaboration agreements are disclosed in Note 1.1 and 6.

F-84

Contingencies and litigations

The Company is exposed to contingent liabilities relating to legal actions before the labor court or intellectual property issues happening in the ordinary course of its activities. Each pre-litigation, known litigation or procedure in ordinary course the Company is involved in was analyzed at the closing date after consultation of advisors.

Provisions

Provisions amounted to € 1,740 774 481

As of December 31,2024, they mainly consist of provision for employer contribution in respect of the grants of employee equity instruments for an amount of € 394 566

As a reminder, as of December 31, 2022, they mainly consist of (i) a provision amounting to € 1,270

In accordance with IFRS 2, when a Company decides to provide its employees with shares bought back on the market, a provision has to be recognized upon the decision to allocate free shares that are spread over the vesting period when the plan conditions actions for employees when they join the Company at the end of the plan.

19)Related party transactions

Members of the Executive Board and Leadership Team

For each of the periods presented, the following compensation was granted to the members of the Leadership Team of the Company and